WO2012071096A3 - Arid1a and ppp2r1a mutations in cancer - Google Patents

Arid1a and ppp2r1a mutations in cancer Download PDF

Info

Publication number
WO2012071096A3
WO2012071096A3 PCT/US2011/050487 US2011050487W WO2012071096A3 WO 2012071096 A3 WO2012071096 A3 WO 2012071096A3 US 2011050487 W US2011050487 W US 2011050487W WO 2012071096 A3 WO2012071096 A3 WO 2012071096A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
ppp2r1a
arid1a
diagnosis
mutations
Prior art date
Application number
PCT/US2011/050487
Other languages
French (fr)
Other versions
WO2012071096A2 (en
Inventor
Bert Vogelstein
Kenneth W. Kinzler
Victor Velculescu
Nickolas Papadopoulos
Sian Jones
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to US13/819,933 priority Critical patent/US9982304B2/en
Publication of WO2012071096A2 publication Critical patent/WO2012071096A2/en
Publication of WO2012071096A3 publication Critical patent/WO2012071096A3/en
Priority to US15/987,235 priority patent/US20180327863A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Two genes, ARID1A (AT-rich interactive domain-containing protein 1A) and PPP2R1A (protein-phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer, diagnosing cancer, contributing to a diagnosis of cancer, confirming a diagnosis of cancer, identifying appropriate treatments for cancer, monitoring treatment of cancer, and evaluating treatment protocols for cancer, including ovarian clear cell carcinoma, breast cancer, colon cancer, gastric cancer, lung cancer, medulloblastoma, pancreatic cancer, and prostate cancer.
PCT/US2011/050487 2010-09-03 2011-09-06 Arid1a and ppp2r1a mutations in cancer WO2012071096A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/819,933 US9982304B2 (en) 2010-09-03 2011-09-06 ARID1A and PPP2R1A mutations in cancer
US15/987,235 US20180327863A1 (en) 2010-09-03 2018-05-23 Arid1a and ppp2r1a mutations in cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37987510P 2010-09-03 2010-09-03
US61/379,875 2010-09-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/819,933 A-371-Of-International US9982304B2 (en) 2010-09-03 2011-09-06 ARID1A and PPP2R1A mutations in cancer
US15/987,235 Division US20180327863A1 (en) 2010-09-03 2018-05-23 Arid1a and ppp2r1a mutations in cancer

Publications (2)

Publication Number Publication Date
WO2012071096A2 WO2012071096A2 (en) 2012-05-31
WO2012071096A3 true WO2012071096A3 (en) 2012-08-16

Family

ID=46146345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/050487 WO2012071096A2 (en) 2010-09-03 2011-09-06 Arid1a and ppp2r1a mutations in cancer

Country Status (2)

Country Link
US (2) US9982304B2 (en)
WO (1) WO2012071096A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6351182B2 (en) * 2012-10-15 2018-07-04 エピザイム，インコーポレイティド How to treat cancer
ES2674928T3 (en) * 2012-11-05 2018-07-05 Gmdx Co Pty Ltd Methods to determine the cause of somatic mutagenesis
US10815522B2 (en) 2015-02-20 2020-10-27 The Johns Hopkins University Genomic alterations in the tumor and circulation of pancreatic cancer patients
MX2018002344A (en) 2015-08-24 2018-07-06 Epizyme Inc Method for treating cancer.
CN108504637A (en) * 2017-07-10 2018-09-07 复旦大学附属肿瘤医院 Chinese's clear cell carcinoma of ovary cell line
CN114555802A (en) * 2019-07-31 2022-05-27 铂赛基因组学公司 Single cell analysis
WO2021173960A1 (en) * 2020-02-28 2021-09-02 The Wistar Institute Of Anatomy And Biology Treatment of carm1-overexpressing and/or arid1a mutant cancers with ire-1/xbp-1 inhibitors
US20230176059A1 (en) * 2020-05-01 2023-06-08 Mayo Foundation For Medical Education And Research Methods and materials for treating endometrial cancer
WO2022020359A1 (en) * 2020-07-24 2022-01-27 The Regents Of The University Of Michigan Compositions and methods for detecting and treating high grade subtypes of uterine cancer
WO2022056457A1 (en) * 2020-09-14 2022-03-17 The Johns Hopkins University Methods and compositions for prognosing glioblastoma or breast cancer
CN116019916A (en) * 2021-10-27 2023-04-28 蚌埠医学院第一附属医院 Application of non-small cell lung cancer target ARID1A and inhibitor thereof in preparation of lung cancer treatment drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5965377A (en) 1997-03-24 1999-10-12 Baystate Medical Center Method for determining the presence of mutated BRCA protein
DK2245199T3 (en) * 2008-02-01 2014-02-03 Gen Hospital Corp APPLICATION OF MICROVESCIES IN DIAGNOSTICATION, PROGRAMMING AND TREATMENT OF MEDICAL DISEASES AND CONDITIONS

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CALIN, G. A. ET AL.: "Low frequency of alterations of the a(PPP2R1A) and b(PPP2RIB) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms", ONCOGENE, vol. 19, 24 February 2000 (2000-02-24), pages 1191 - 1195 *
HUNG, J. ET AL.: "Genomic and functional evidence for an ARID1A tumor suppressor role", GENES, CHROMOSOMES & CANCER, vol. 46, 10 May 2007 (2007-05-10), pages 745 - 750 *
JONES, S. ET AL.: "Frequent mutations of chromatin remodeling gene ARIDIA in ovarian clear cell carcinoma", SCIENCE, vol. 330, no. 6001, 8 October 2010 (2010-10-08), pages 228 - 231 *
MAEDA, D. ET AL.: "Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE, vol. 11, 13 December 2010 (2010-12-13), pages 5120 - 5128 *
MCCONECHY, M. K. ET AL.: "Subtype-specific mutation of PPP2RIA in endometrial and ovarian carcinomas", JOURNAL OF PATHOLOGY, vol. 223, April 2011 (2011-04-01), pages 567 - 573 *
WIEGAND, K. C. ET AL.: "ARIDIA mutations in endometriosis associated ovarian carcinomas", NEW ENGLAND JOURNAL OF MEDICINE, vol. 363, no. 16, 14 October 2010 (2010-10-14), pages 1532 - 1543 *

Also Published As

Publication number Publication date
US20180327863A1 (en) 2018-11-15
US9982304B2 (en) 2018-05-29
US20130210900A1 (en) 2013-08-15
WO2012071096A2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
WO2012071096A3 (en) Arid1a and ppp2r1a mutations in cancer
WO2013181543A8 (en) High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2010072383A8 (en) Armet as a marker for cancer
HK1187377A1 (en) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
WO2012017430A3 (en) Microrna patterns for the diagnosis, prognosis and treatment of melanoma
HK1208501A1 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
PL2223115T3 (en) Seprase as a marker for cancer
MX2013000502A (en) Methods and kits for the diagnosis of prostate cancer.
EP2576837A4 (en) Prostate cancer associated circulating nucleic acid biomarkers
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2611941A4 (en) Gene signatures for cancer diagnosis and prognosis
WO2011008262A9 (en) Methods and apparatus for diagnosis and/or prognosis of cancer
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
EP2596132A4 (en) Methods for detecting signatures of disease or conditions in bodily fluids
EP2524059A4 (en) Detection of gastrointestinal disorders
AU2012356133A8 (en) A rapid quantitative assay to measure CFTR function in a primary intestinal culture model
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2011015602A3 (en) Lung cancer biomarkers
WO2009083780A8 (en) Breast cancer expression profiling
MX352373B (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof.
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
GB201603128D0 (en) Biomarkers useful for detection of types, grades and stages of human breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11843973

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13819933

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11843973

Country of ref document: EP

Kind code of ref document: A2